openPR Logo
Press release

Pace of Change Makes the Market for Generic Injectables a Moving Target

04-06-2016 06:02 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – Along with the ability to create therapeutic replicas of biochemicals via host systems, the emergence and proliferation of generic drugs continue to re-shape the therapeutic landscape. Generics have grown from a cottage industry two decades ago to a burgeoning subset of the pharmaceutical sector. The pace of activity in generics has centered on oral dosage forms. The next new hot market is injectables.

There are 235 distinct APIs that account for at least one approved generic injectable. These 235 APIs represent 1,167 distinct ANDAs. Including all approved doses, the current universe of generic injectables consists of 1,699 injectable products. These products are marketed and supplied by a growing list of one hundred companies.

In terms of generic products, antibiotics are the largest and most competitive segment, representing a quarter of the total generic injectables market on a product basis. The remainder are spread over three dozen drug classes. The top three companies account for a third of all products, with the top ten companies accounting for just under half.

The competitive climate varies across drug and therapeutic classes. In addition to antibiotics, the most competitive drug segments include anti-arrhythmics, anesthetics, anticoagulants, anticonvulsants, anti-hypertensives and anti-emetics.

Looking to the future, patent expirations on branded injectables will continue to keep this market growing. For 2016, fourteen drugs will see a total of twenty-seven Orange Book-listed patents expire. For the remainder of the decade, 193 patents covering 55 injectables are set to end.

Complicating the competitive picture will be the continuation of asset deals and M&A activity. Pfizer’s acquisition of Hospira – the largest generic injectables supplier by product count – is a recent example of how the market is changing as companies attempt to stake out positions in a segment that will continue to experience strong growth.

Generic injectables are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Generic Injectables – Products, Markets, Players and Outlook analyzes generic injectable products and the indications and therapeutic classes in which they compete. The report includes analysis of competitive factors, ANDA filing strategies, market growth trends and strategic and economic factors, and provides assessments of the market presence of sector participants.

More information is available at http://www.greystoneassociates.org


Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pace of Change Makes the Market for Generic Injectables a Moving Target here

News-ID: 330839 • Views: 646

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for Generic

A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S and Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Global Generic Drugs Market Research Report 2017
In this report, the global Generic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Generic Drugs in these regions, from 2012 to 2022 (forecast), covering North
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of